Zhang et al.’s 2022 pan-cancer analysis of 45,604 patients with diverse tumors identified non-melanoma skin cancers having the highest frequency of PARP1 mutations among cancer types (8.98%, 44/490) [57]. This evidence concerns the gene PARP1 and non-melanoma skin carcinoma.